A new technology using sound waves was shown to be effective at separating circulating tumor cells (CTCs) from clinical blood samples. The acoustic pressure device, developed in a Duke University laboratory, is gentle enough to separate CTCs without damaging them allowing the cells to maintain normal function and grow outside of the body. The technology could potentially be used in the first FDA-approved device for CTC detection that can also grow CTCs after they’ve been isolated from blood samples. There’s currently only one clinically approved device for counting and basic characterization of CTCs since the cells become too damaged in the process to analyze them further. The results of the study were published today in Small.
A sound wave flows through the device at an angle to the fluid flowing through a narrow channel. Pockets of pressure pushes on cells and particles flowing through the liquid as they pass through the channel. The sound wave pushes with more force on cancer cells since they are larger than blood cells which pushes the CTCs into a separate channel where they can easily be isolated. The acoustic wave only acts on the cells for a fraction of a second minimizing damage to the cells. In addition, no labeling or other modifications need to be made to the tumor cells which keeps them in their native state and functioning normally.
"The biggest asset of this acoustic method of separation is that it's very gentle on the circulating tumor cells," said Andrew Armstrong, associate professor of medicine, surgery, and pharmacology and cancer biology at the Duke University School of Medicine. "The cancer cells remain viable after passing through the chip and can be characterized, cultured or profiled, which allows us to do genotyping or phenotyping to better understand how to kill them."
The paper describes how the technology was used to collect CTCs from prostate cancer patients and the researchers were able to successfully profile them for biomarkers and growth characteristics. Levels of prostate-specific membrane antigen (PSMA), a biomarker commonly used for imaging and treatment in the clinic, were found to vary among patient samples. Information like this could help clinicians develop more personalized and effective cancer treatments.